Palisade Bio, Inc. announced that Effective October 11, 2022 (the Effective Date), the employment of Michael Dawson, MD, was terminated. Accordingly, on the Effective Date, Dr. Dawson ceased performing the duties of Chief Medical Officer for the Company.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.82 USD | +3.54% | -1.83% | -45.54% |
05-21 | Palisade Bio, Inc. Announces Presentation of Positive Preclinical Data from PALI-2108 | CI |
05-13 | Palisade Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-45.54% | 4.51M | |
+43.36% | 54.63B | |
-5.31% | 39.92B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B | |
-11.83% | 10.74B |
- Stock Market
- Equities
- SNCA Stock
- News Palisade Bio, Inc.
- Palisade Bio, Inc. Terminates Michael Dawson as Chief Medical Officer